drugset / Trial / NCT00926289
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3 hypertension (SBP\>=160 mmHg and Diastolic Blood Pressure(DBP)\>=100 mmHg).
Timeline
- Start
- 2009-06
- Primary completion
- 2010-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrochlorothiazide | Unknown | 25 mg | — |
| Subject | Telmisartan | Other / unclassified | 80 mg | — |